05995nam 2201681z- 450 991036756660332120231214132829.03-03921-392-X(CKB)4100000010106080(oapen)https://directory.doabooks.org/handle/20.500.12854/49693(EXLCZ)99410000001010608020202102d2019 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierHurdles for Phage Therapy (PT) to Become a RealityMDPI - Multidisciplinary Digital Publishing Institute20191 electronic resource (484 p.)3-03921-391-1 Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.Hurdles for Phage Therapy alginateabortive infectionbacterial resistancebacteriophagesATMPMALDI-MSadaptationBacteriophagehorizontal gene transferadaptive immunityco-evolutionListeria ivanoviipersonalised medicinespH stabilityphage-human host interactionvB_SauM-fRuSau02antimicrobial resistancephagodisinfectionbiofilmcapsule depolymeraseanimal modelphage cocktailsEnterococcuscases reportzoonosisresistancemagistral formulaexperimental therapyBelgiumphage therapyE. faecalisnontraditional antibacterialindustrial phage applicationDemocratic Republic of the CongoOrthoMCLGermanyhigh-throughput sequencingantimicrobialinfectionantibiotic therapyKayvirusphagesTwortlikevirusbacterial diseasehuman hostPseudomonas aeruginosaphagemultidrug-resistant bacteriabacterial infectionSalmonella Typhirhamnopolysaccharidecompassionate usecrop productioncompounding pharmacyantimicrobial resistance (AMR)best practicesbacteriophage efficacyphage sensitivityantibiotic-resistanceantibioticlysinsPTMPEscherichia colityphoid feverpatent landscapephage preparationinnate immunityanti-phage antibodiesimmunologyStaphylococcus aureusglobal healthclinical trialadsorptionBrusselsphage-resistanceGalleria mellonellascience communicationhistory of sciencevirus-host interactionsfoodborne illnessprophageresistance managementbiofilmsINDimmunomodulationfrequency of resistancecapsulegastrointestinal tractphage-host interactionsdisinfectionproductionbacteriophage therapybacteriophageStaphylococcusmagistral preparationextended-spectrum beta lactamases (ESBL)Viral proteinsantibiotic resistancegenomicsphage biocontroltherapytarget selectionviral genomesevolutionpharmaceutical paradigm shiftpersonalized medicinepharmaceutical legislationfood safetyregulationvirulencedeveloping countriesinfectious diseaseregulatory frameworksustainable agricultureKlebsiella pneumoniaeBrüssow Haraldauth1331097BOOK9910367566603321Hurdles for Phage Therapy (PT) to Become a Reality3040125UNINA